Esperion Therapeutics (ESPR) Equity Ratio (2018 - 2025)
Esperion Therapeutics' Equity Ratio history spans 8 years, with the latest figure at 0.65 for Q4 2025.
- For Q4 2025, Equity Ratio rose 42.67% year-over-year to 0.65; the TTM value through Dec 2025 reached 0.65, up 42.67%, while the annual FY2025 figure was 0.65, 42.67% up from the prior year.
- Equity Ratio reached 0.65 in Q4 2025 per ESPR's latest filing, up from 1.24 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.52 in Q4 2021 to a low of 2.21 in Q4 2023.
- Average Equity Ratio over 5 years is 1.18, with a median of 1.15 recorded in 2024.
- Peak YoY movement for Equity Ratio: crashed 4610.13% in 2021, then soared 48.86% in 2024.
- A 5-year view of Equity Ratio shows it stood at 0.52 in 2021, then plummeted by 153.02% to 1.31 in 2022, then plummeted by 69.3% to 2.21 in 2023, then skyrocketed by 48.86% to 1.13 in 2024, then surged by 42.67% to 0.65 in 2025.
- Per Business Quant, the three most recent readings for ESPR's Equity Ratio are 0.65 (Q4 2025), 1.24 (Q3 2025), and 1.25 (Q2 2025).